Leishmania donovani nitroreductase 1 (LdNTR1)

Leishmania donovani nitroreductase 1 (LdNTR1) is an essential FMN-dependent, NADH-utilizing enzyme primarily located in the mitochondria of the parasite responsible for visceral leishmaniasis. It belongs to the type I (oxygen-insensitive) nitroreductase family, which is notably absent in mammalian cells, providing a clear basis for selective therapeutic targeting. The enzyme's primary pharmacological role is the reductive bioactivation of nitroheterocyclic prodrugs, such as fexinidazole. By reducing the nitro group of these compounds, LdNTR1 generates reactive cytotoxic species that induce significant DNA damage and proteotoxic stress, leading to parasite death. Because LdNTR1 is genetically essential for the survival and growth of the parasite, it is a high-priority target for the development of new antileishmanial therapies. However, its central role in drug activation also makes it a focal point for the development of clinical resistance, as mutations that reduce enzyme activity can significantly decrease drug efficacy.

Other names

Type I nitroreductaseOxygen-insensitive nitroreductaseNADH-dependent nitroreductaseLdNTRNTR1

Reductive activation of nitroaromatic and nitroheterocyclic prodrugs into highly reactive, cytotoxic metabolites (such as nitro radicals and hydroxylamine derivatives) that cause lethal DNA damage and oxidative stress within the parasite.